Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Köhler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbücher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-Incio D, Linden G, Skottky S, Lütkes P, Dechêne A, Paul A, Markus P, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: theegarten d. Eur J Cancer. 2013 Oct;49(15):3076-82. doi: 10.1016/j.ejca.2013.06.014. Epub 2013 Jul 19. Eur J Cancer. 2013. PMID: 23876834
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors.
Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, Freitag L, Jawad JA, Gkika E, Wohlschlaeger J, Welter S, Hoiczyk M, Schuler M, Stamatis G, Eberhardt W. Pöttgen C, et al. Among authors: theegarten d. BMC Cancer. 2015 May 6;15:363. doi: 10.1186/s12885-015-1389-4. BMC Cancer. 2015. PMID: 25943191 Free PMC article.
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE. Guberina N, et al. Among authors: theegarten d. Eur J Cancer. 2020 Oct;138:156-168. doi: 10.1016/j.ejca.2020.07.025. Epub 2020 Sep 2. Eur J Cancer. 2020. PMID: 32889370
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, Abu Jawad J, Wohlschlaeger J, Welter S, Stamatis G, Stuschke M. Pöttgen C, et al. Among authors: theegarten d. Eur J Cancer. 2013 Jun;49(9):2107-15. doi: 10.1016/j.ejca.2013.02.030. Epub 2013 Mar 16. Eur J Cancer. 2013. PMID: 23510803
Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study.
Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus SY, Theegarten D, Schmid KW, Wohlschlaeger J. Mairinger FD, et al. Among authors: theegarten d. Mod Pathol. 2014 Dec;27(12):1632-40. doi: 10.1038/modpathol.2014.74. Epub 2014 May 30. Mod Pathol. 2014. PMID: 24875640 Free article.
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Schmid KW, Wohlschlaeger J. Mairinger FD, et al. Among authors: theegarten d. J Cancer. 2014 Aug 1;5(8):646-54. doi: 10.7150/jca.9955. eCollection 2014. J Cancer. 2014. PMID: 25157275 Free PMC article.
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: theegarten d. J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27. J Thorac Oncol. 2017. PMID: 27575422 Free article.
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.
Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. Oezkan F, et al. Among authors: theegarten d. Clin Lung Cancer. 2018 Nov;19(6):e879-e884. doi: 10.1016/j.cllc.2018.08.016. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30206042
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C. Guberina M, et al. Among authors: theegarten d. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323 Clinical Trial.
184 results